PHARMAIDS PHARMACEUTICALS LTD.
NSE : NABSE : 524572ISIN
CODE : INE117D01018Industry : Pharmaceuticals & DrugsHouse
: Private
BSE57.351.12 (+1.99 % )
PREV CLOSE (Rs.) 56.23
OPEN PRICE (Rs.) 57.35
BID PRICE (QTY) 56.23 (1 )
OFFER PRICE (QTY) 57.35 (730 )
VOLUME 1770
TODAY'S LOW / HIGH (Rs.)
52 WK LOW / HIGH (Rs.)
NSE
This Company is not listed in NSE
Company News
| Date | Heading | Details |
|---|---|---|
| 13-May-2024 | Pharmaids Pharmaceutical informs about compliance report | <p style="text-align: justify;">Pursuant to Regulation 24A of the Listing Regulations read with SEBI Circular No. CIR/CFD/CMDI/ 27/2019 dated February 8 2019 and Circular No: NSE/CML/ 2023/30 dated April 10, 2023, Pharmaids Pharmaceutical has informed that it enclosed the Annual Secretarial Compliance Report for the Financial Year ended March 31, 2024, issued by Kashinath Sahu & Co, Practicing Company Secretary.</p><div>The above information is a part of company's filings submitted to BSE.</div> |
| 26-Mar-2024 | Pharmaids Pharmaceuticals informs about disclosure | <div style="text-align: justify;">In terms of Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015, Pharmaids Pharmaceuticals has informed about disclosure received from Shiromani Vijay (Immediate Relative of the Designated Person) in Form ‘B' in respect to Purchase of Equity Shares of the Company pursuant to the Regulation 7(2)(a) of SEBI (Prohibition of Insider Trading) Regulations, 2015. </div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 06-Mar-2024 | Pharmaids Pharmaceuticals informs about disclosure | <p style="text-align: justify;">Pharmaids Pharmaceuticals has informed that the exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Gokaram Ramkrishna Balaji.</p><p style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</p> |
| 05-Mar-2024 | Allotment of Equity Shares | Inter alia, approved the allotment of 1,28,56,578 fully paid-up equity shares having face value of Rs.10/-(Rupees Ten Only) each at a price of Rs.40.87/- (including premium of Rs.30.87/-) per equity shares to the allottees given below as an Annexure A, for the consideration other than cash (i.e., being a full consideration for acquisition of 36,73,308 equity shares of Rs.10/- (Rupees Ten Only) each of Adita Bio Sys Private Limited (?target company?), on preferential basis by way of private placement. These shares shall rank pari-passu, in all respects with the existing equity shares of the company. The company has received in-principle approval from the Stock Exchange i.e., BSE Limited for issue of the aforesaid Equity Shares on Preferential Basis on February 19, 2024. The Application for listing approval of the stock exchange for the equity shares allotted as above will be made in due course. |
| 04-Mar-2024 | H.G. Infra Engineering, Coal India and Avenue Supermarts to see some action today | <p style="text-align: justify;"><span style="font-weight: bold;">H.G. Infra Engineering </span>has received the Letter of Acceptance (LoA) from South Central Railway for Doubling of Track between Karanjgaon station (Including) at Km 69.01(Ch 69010) & Aurangabad station (Including) at Km 113.15 (Ch 113150) [i.e. (44.14 km)] including Electrification and Signaling works in connection with Aurangabad-Ankai Doubling Project in Nanded Division of South-Central Railway. The project cost is Rs 447.11 crore and the construction period is 30 months.</p><p style="text-align: justify;"><span style="font-weight: bold;">Coal India</span> has entered into Memorandum of Understanding (MoU) with Indian Institutes of Management (IIM) Mumbai and Sambalpur on March 1, 2024, marking a crucial step in multimodal connectivity infrastructure for coal transportation in alignment with the PM Gati Shakti National Master Plan 2021.</p><p style="text-align: justify;"><span style="font-weight: bold;">Avenue Supermarts </span>has opened a new store at Hesaraghatta Road, Bengaluru (Karnataka). The total number of stores as on date stands at 347.</p><p style="text-align: justify;"><span style="font-weight: bold;">Lemon Tree Hotels</span> has signed - Keys Lite by Lemon Tree Hotels, Urban Suites, Udaipur. The property, which will be franchised by Lemon Tree Hotels, is expected to open in FY25. Udaipur is often referred to as the Venice of the East on account of the seven turquoise lakes that dot the city. Bound by the verdant Aravalli hills, Udaipur holds a variety of attractions for its visitors including history, culture, scenic locations, opulent Rajput-era palaces and vibrant markets. </p><p style="text-align: justify;"><span style="font-weight: bold;">Indian Railway Catering and Tourism Corporation</span> (IRCTC) has signed Memorandum of Understanding (MoU) with CRPF on March 1, 2024 for On-board Catering services to allCAPF (CRPF, ITBP, BSF, CISF & SSB) personnel during movement for various law & order duties including Bye-elections.</p><p style="text-align: justify;"><span style="font-weight: bold;">Alfa Transformers</span> has received a purchase order worth of Rs 27.39 crore from Gujarat Electricity Board. The company has bagged order for design, manufacturing and supply of 10 KVA 4,994 Nos of transformers from Vadodara plant. The said order is to be executed within 7 months from the date of receipt of order. </p><p style="text-align: justify;"><span style="font-weight: bold;">Pharmaids Pharmaceuticals </span>has completed the acquisition of 99.86% shareholding in Adita Bio Sys (Adita). Adita is an unlisted private company, which is engaged in the GLP Developmental Services, Drug Discovery & Laboratory animals services & Animal Diet. The acquisition of the shares of Adita inter alia result in growth opportunities in line with strategic objectives of the Company. The acquisition of the target entity is within the main line of business of the listed entity. The cost of acquisition is Rs 52.54 crore. </p> |
| 02-Mar-2024 | Pharmaids Pharmaceuticals acquires 99.86% shareholding in Adita Bio Sys | <p style="text-align: justify;">Pharmaids Pharmaceuticals has completed the acquisition of 99.86% shareholding in Adita Bio Sys (Adita). Adita is an unlisted private company, which is engaged in the GLP Developmental Services, Drug Discovery & Laboratory animals services & Animal Diet. The acquisition of the shares of Adita inter alia result in growth opportunities in line with strategic objectives of the Company. The acquisition of the target entity is within the main line of business of the listed entity. The cost of acquisition is Rs 52.54 crore. </p><p style="text-align: justify;">Pharmaids Pharmaceuticals is engaged in the business of trading and manufacturing of generics, bulk drugs and intermediaries etc.</p> |
| 02-Mar-2024 | Pharmaids Pharmaceuticals informs about allotment of equity shares | <div style="text-align: justify;">Pharmaids Pharmaceuticals has informed that Board of Directors of the Company at its meeting held on March 02, 2024 approved the allotment of 12856578 fully paid-up Equity Shares for the Consideration other than cash on Preferential Basis by way of Private Placement. The details as required under Regulation 30 of Listing Regulations read with SEBI Circular dated July 13, 2023 are given in the attached intimation.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 02-Mar-2024 | Pharmaids Pharmaceuticals informs about outcome for board meeting | <div>Pharmaids Pharmaceuticals has informed that the Board of Directors of Pharmaids Pharmaceuticals (the Company) at its meeting held today, i.e., March 02, 2024, approved the allotment of 1,28,56,578 fully paid-up equity shares having face value of Rs 10 (Rupees Ten Only) each at a price of Rs 40.87 (including premium of Rs 30.87) per equity shares to the allottees given below as an Annexure A, for the consideration other than cash (i.e., being a full consideration for acquisition of 36,73,308 equity shares of Rs 10 (Rupees Ten Only) each of Adita Bio Sys (target company), on preferential basis by way of private placement. These shares shall rank pari-passu, in all respects with the existing equity shares of the company. The company has received in-principle approval from the Stock Exchange i.e., BSE for issue of the aforesaid Equity Shares on Preferential Basis on February 19, 2024. The Application for listing approval of the stock exchange for the equity shares allotted as above will be made in due course. The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular on Continuous Disclosure (SEBI Circular SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023), regarding the issue of equity shares on a preferential basis is enclosed as Annexure-I. The Board Meeting commenced at 11:30 am and concluded at 12:40 pm.</div><div><br></div><div>The above information is a part of company's filings submitted to BSE.</div> |
| 12-Feb-2024 | Pharmaids Pharmaceuticals informs about disclosure | <div style="text-align: justify;">Pharmaids Pharmaceuticals has informed that the company has received request letters from Veena Lalwani, Abhilekha Jain, Ghisulal Jain, Subhash Lalwani and Abhishek Jain, members belonging to ‘Promoter and promoter group' seeking reclassification from ‘promoter and promoter group' to ‘Public Shareholders'. The Request will be reviewed and shall be considered by the Board of Directors in the forthcoming Board meeting in accordance with provisions of Regulation 31A of the SEBI (LODR) Regulations, 2015.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div> |
| 10-Jan-2024 | Pharmaids Pharmaceuticals informs about compliances-certificate | <div style="text-align: justify;">Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, Pharmaids Pharmaceuticals has enclosed the Certificate received from Venture Capital and Corporate Investments (SEBI Registration No. INR000001203), Registrar and Share Transfer Agent of the Company, for the Quarter ended December 31, 2023, confirming the compliances completed with respect to dematerialization of the shares, in terms of the said Regulation.</div><div style="text-align: justify;"><br></div><div style="text-align: justify;">The above information is a part of company's filings submitted to BSE.</div><div style="text-align: justify;"><br></div> |
